FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:775-789 February 22, 2007 Number 8 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set CME Exam Supplementary Material Editorial by Rabe, K. F. Letters Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Long-acting beta-agonists and inhaled corticosteroids are used to treat chronic obstructive pulmonary disease (COPD), but their effect on survival is unknown.

Methods We conducted a randomized, double-blind trial comparing salmeterol at a dose of 50 µg plus fluticasone propionate at a dose of 500 µg twice daily (combination regimen), administered with a single inhaler, with placebo, salmeterol alone, or fluticasone propionate alone for a period of 3 years. The primary outcome was death from any cause for the comparison between the combination regimen and placebo; the frequency of exacerbations, health status, and spirometric values were also assessed.

Results Of 6112 patients in the efficacy population, 875 died within 3 years after the start of the study treatment. All-cause mortality rates were 12.6% in the combination-therapy group, 15.2% in the placebo group, 13.5% in the salmeterol group, and 16.0% in the fluticasone group. The hazard ratio for death in the combination-therapy group, as compared with the placebo group, was 0.825 (95% confidence interval [CI], 0.681 to 1.002; P=0.052, adjusted for the interim analyses), corresponding to a difference of 2.6 percentage points or a reduction in the risk of death of 17.5%. The mortality rate for salmeterol alone or fluticasone propionate alone did not differ significantly from that for placebo. As compared with placebo, the combination regimen reduced the annual rate of exacerbations from 1.13 to 0.85 and improved health status and spirometric values (P<0.001 for all comparisons with placebo). There was no difference in the incidence of ocular or bone side effects. The probability of having pneumonia reported as an adverse event was higher among patients receiving medications containing fluticasone propionate (19.6% in the combination-therapy group and 18.3% in the fluticasone group) than in the placebo group (12.3%, P<0.001 for comparisons between these treatments and placebo).

Conclusions The reduction in death from all causes among patients with COPD in the combination-therapy group did not reach the predetermined level of statistical significance. There were significant benefits in all other outcomes among these patients. (ClinicalTrials.gov number, NCT00268216 [ClinicalTrials.gov] .)

Source Information

From University Hospital Aintree, Liverpool, United Kingdom (P.M.A.C.); GlaxoSmithKline Research and Development, Greenford, United Kingdom (J.A.A.); Caritas St. Elizabeth's Medical Center, Boston (B.C.); Pulmonary Research Institute of Southeast Michigan, Livonia (G.T.F.); Woolcock Institute of Medical Research, Sydney (C.J.); St. George's University of London, London (P.W.J.); GlaxoSmithKline Research and Development, Research Triangle Park, NC (J.C.Y.); and Wythenshawe Hospital, Manchester, United Kingdom, and Hvidovre Hospital, Hvidovre, Denmark (J.V.).

Address reprint requests to Dr. Calverley at the Department of Medicine, Clinical Science Centre, University Hospital Aintree, Longmoor Lane, Liverpool L9 7AL, United Kingdom, or at pmacal{at}liverpool.ac.uk.

Full Text of this Article

Related Letters:

Prevention of Death in COPD
Barnes P. J., La Vecchia C., Fabbri L. M., Duerden M., Kupfer Y., Tessler S., Keaney N., Calverley P., Anderson J., Celli B.
Extract | Full Text | PDF  
N Engl J Med 2007; 356:2211-2214, May 24, 2007. Correspondence

Treating COPD
Kiley J. P., Nabel E. G.
Extract | Full Text | PDF  
N Engl J Med 2007; 356:867, Feb 22, 2007. Correspondence

This article has been cited by other articles:

• Donohue, J. F., Hanania, N. A., Fogarty, C., Campbell, S. C., Rinehart, M., Denis-Mize, K. (2008). Long-term safety of nebulized formoterol: Results of a twelve-month open-label clinical trial. Therapeutic Advances in Respiratory Disease 2: 199-208 [Abstract]  
• Keene, O. N., Calverley, P. M. A., Jones, P. W., Vestbo, J., Anderson, J. A. (2008). Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited. Eur Respir J 32: 17-24 [Abstract] [Full Text]  
• Mendes, E. S., Horvath, G., Rebolledo, P., Monzon, M. E., Casalino-Matsuda, S. M., Wanner, A. (2008). Effect of an inhaled glucocorticoid on endothelial function in healthy smokers. J. Appl. Physiol. 105: 54-57 [Abstract] [Full Text]  
• Gillissen, A. (2008). Is Salmeterol/Fluticasone Propionate Equivalent to Tiotropium Bromide in the Treatment of COPD?. Am. J. Respir. Crit. Care Med. 178: 105-105 [Full Text]  
• Middleton, P. G. (2008). Management of Patients with COPD: A Comparison of the INSPIRE and TORCH Studies. Am. J. Respir. Crit. Care Med. 178: 106-106 [Full Text]  
• Benfield, T., Lange, P., Vestbo, J. (2008). COPD Stage and Risk of Hospitalization for Infectious Disease. Chest 134: 46-53 [Abstract] [Full Text]  
• Wedzicha, J. A., Calverley, P. M. A., Seemungal, T. A., Hagan, G., Ansari, Z., Stockley, R. A., for the INSPIRE Investigators, (2008). Management of Patients with COPD: A Comparison of the INSPIRE and TORCH Studies. Am. J. Respir. Crit. Care Med. 178: 106-107 [Full Text]  
• Singh, D, Brooks, J, Hagan, G, Cahn, A, O'Connor, B J (2008). Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax 63: 592-598 [Abstract] [Full Text]  
• Shafazand, S. (2008). Review: corticosteroids plus LABAs reduce exacerbations and mortality more than steroids alone in COPD. Evid. Based Med. 13: 74-74 [Full Text]  
• Chung, K. F., Adcock, I. M. (2008). Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction. Eur Respir J 31: 1334-1356 [Abstract] [Full Text]  
• Celli, B. R. (2008). Update on the Management of COPD. Chest 133: 1451-1462 [Abstract] [Full Text]  
• Almirall, J., Bolibar, I., Serra-Prat, M., Roig, J., Hospital, I., Carandell, E., Agusti, M., Ayuso, P., Estela, A., Torres, A., the Community-Acquired Pneumonia in Catalan Countr, (2008). New evidence of risk factors for community-acquired pneumonia: a population-based study. Eur Respir J 31: 1274-1284 [Abstract] [Full Text]  
• Chang, K. C., Leung, C. C., Tam, C. M. (2008). Inhaled Corticosteroids Might Not Protect against Lung Cancer. Am. J. Respir. Crit. Care Med. 177: 1290-1290 [Full Text]  
• Au, D. H., Chien, J. W., Bryson, C. L. (2008). Inhaled Corticosteroids Might Not Protect against Lung Cancer. Am. J. Respir. Crit. Care Med. 177: 1290-1291 [Full Text]  
• Sin, D. D., Man, S. F. P., Marciniuk, D. D., Ford, G., FitzGerald, M., Wong, E., York, E., Mainra, R. R., Ramesh, W., Melenka, L. S., Wilde, E., Cowie, R. L., Williams, D., Gan, W. Q., Rousseau, R., for the ABC (Advair, Biomarkers in COPD) Investiga, (2008). The Effects of Fluticasone with or without Salmeterol on Systemic Biomarkers of Inflammation in Chronic Obstructive Pulmonary Disease. Am. J. Respir. Crit. Care Med. 177: 1207-1214 [Abstract] [Full Text]  
• Todd, D. C., McIvor, R. A., Pugsley, S. O., Cox, G. (2008). Approach to chronic obstructive pulmonary disease in primary care. cfp 54: 706-711 [Abstract] [Full Text]  
• Albert, P., Calverley, P. M. A. (2008). Drugs (including oxygen) in severe COPD. Eur Respir J 31: 1114-1124 [Abstract] [Full Text]  
• Falk, J. A., Minai, O. A., Mosenifar, Z. (2008). Inhaled and Systemic Corticosteroids in Chronic Obstructive Pulmonary Disease. Proc Am Thorac Soc 5: 506-512 [Abstract] [Full Text]  
• Falk, J. A., Kadiev, S., Criner, G. J., Scharf, S. M., Minai, O. A., Diaz, P. (2008). Cardiac Disease in Chronic Obstructive Pulmonary Disease. Proc Am Thorac Soc 5: 543-548 [Abstract] [Full Text]  
• Chatila, W. M., Thomashow, B. M., Minai, O. A., Criner, G. J., Make, B. J. (2008). Comorbidities in Chronic Obstructive Pulmonary Disease. Proc Am Thorac Soc 5: 549-555 [Abstract] [Full Text]  
• Suissa, S., Ernst, P., Vandemheen, K. L., Aaron, S. D. (2008). Methodological issues in therapeutic trials of COPD. Eur Respir J 31: 927-933 [Abstract] [Full Text]  
• Sears, M. R. (2008). Long-Acting Bronchodilators in COPD. Chest 133: 1057-1058 [Full Text]  
• Rodrigo, G. J., Nannini, L. J., Rodriguez-Roisin, R. (2008). Safety of Long-Acting {beta}-Agonists in Stable COPD: A Systematic Review. Chest 133: 1079-1087 [Abstract] [Full Text]  
• Sabroe, I, Parker, L C, Calverley, P M A, Dower, S K, Whyte, M K B (2008). Pathological networking: a new approach to understanding COPD. Postgrad. Med. J. 84: 259-264 [Abstract] [Full Text]  
• MacNee, W. (2008). Update in Chronic Obstructive Pulmonary Disease 2007. Am. J. Respir. Crit. Care Med. 177: 820-829 [Full Text]  
• Oba, Y. (2008). Does Tiotropium Reduce Hospitalizations in Chronic Obstructive Pulmonary Disease?. ANN INTERN MED 148: 626-626 [Full Text]  
• Soriano, J. B., Mannino, D. M. (2008). Reversing concepts on COPD irreversibility. Eur Respir J 31: 695-696 [Full Text]  
• Donohue, J.F., Hanania, N.A., Sciarappa, K.A., Goodwin, E., Grogan, D.R., Baumgartner, R.A., Hanrahan, J.P. (2008). Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: A one year evaluation of safety and tolerance. Therapeutic Advances in Respiratory Disease 2: 37-48 [Abstract]  
• McDonald, C. (2008). Review: long-acting inhaled therapies and pulmonary rehabilitation are effective in stable COPD. Evid. Based Med. 13: 56-56 [Full Text]  
• Lin, K., Watkins, B., Johnson, T., Rodriguez, J. A., Barton, M. B. (2008). Screening for Chronic Obstructive Pulmonary Disease Using Spirometry: Summary of the Evidence for the U.S. Preventive Services Task Force. ANN INTERN MED 148: 535-543 [Abstract] [Full Text]  
• Ernst, P., Suissa, S. (2008). Inhaled Corticosteroids and Pneumonia in COPD: An Association Looking for Evidence. Am. J. Respir. Crit. Care Med. 177: 556-556 [Full Text]  
• Turner, M. O. (2008). Inhaled Corticosteroids and Pneumonia in COPD: An Association Looking for Evidence. Am. J. Respir. Crit. Care Med. 177: 555-556 [Full Text]  
• Smith, C.J.P., Gribbin, J., Challen, K.B., Hubbard, R.B. (2008). The impact of the 2004 NICE guideline and 2003 General Medical Services contract on COPD in primary care in the UK. QJM 101: 145-153 [Abstract] [Full Text]  
• Aaron, S D, Fergusson, D, Marks, G B, Suissa, S, Vandemheen, K L, Doucette, S, Maltais, F, Bourbeau, J F, Goldstein, R S, Balter, M, O'Donnell, D, FitzGerald, M, for the Canadian Thoracic Society/Canadian Respira, (2008). Counting, analysing and reporting exacerbations of COPD in randomised controlled trials. Thorax 63: 122-128 [Abstract] [Full Text]  
• Welte, T. (2008). Acute Exacerbation of Chronic Obstructive Pulmonary Disease: More a Functional than an Inflammatory Problem?. Am. J. Respir. Crit. Care Med. 177: 130-131 [Full Text]  
• Washko, G. R., Fan, V. S., Ramsey, S. D., Mohsenifar, Z., Martinez, F., Make, B. J., Sciurba, F. C., Criner, G. J., Minai, O., DeCamp, M. M., Reilly, J. J., for the National Emphysema Treatment Trial Researc, (2008). The Effect of Lung Volume Reduction Surgery on Chronic Obstructive Pulmonary Disease Exacerbations. Am. J. Respir. Crit. Care Med. 177: 164-169 [Abstract] [Full Text]  
• Fabbri, L. M., Luppi, F., Beghe, B., Rabe, K. F. (2008). Complex chronic comorbidities of COPD. Eur Respir J 31: 204-212 [Abstract] [Full Text]  
• Wedzicha, J. A., Calverley, P. M. A., Seemungal, T. A., Hagan, G., Ansari, Z., Stockley, R. A., for the INSPIRE Investigators, (2008). The Prevention of Chronic Obstructive Pulmonary Disease Exacerbations by Salmeterol/Fluticasone Propionate or Tiotropium Bromide. Am. J. Respir. Crit. Care Med. 177: 19-26 [Abstract] [Full Text]  
• Kaur, M., Chivers, J. E., Giembycz, M. A., Newton, R. (2008). Long-Acting 2-Adrenoceptor Agonists Synergistically Enhance Glucocorticoid-Dependent Transcription in Human Airway Epithelial and Smooth Muscle Cells. Mol. Pharmacol. 73: 203-214 [Abstract] [Full Text]  
• McAllister, D. A., Maclay, J. D., Mills, N. L., Mair, G., Miller, J., Anderson, D., Newby, D. E., Murchison, J. T., MacNee, W. (2007). Arterial Stiffness Is Independently Associated with Emphysema Severity in Patients with Chronic Obstructive Pulmonary Disease. Am. J. Respir. Crit. Care Med. 176: 1208-1214 [Abstract] [Full Text]  
• Rennard, S. I., Higenbottam, T. (2007). Exacerbation-Free COPD: A Goal Too Far?. Proc Am Thorac Soc 4: 583-585 [Abstract] [Full Text]  
• Silverman, E. K. (2007). Exacerbations in Chronic Obstructive Pulmonary Disease: Do They Contribute to Disease Progression?. Proc Am Thorac Soc 4: 586-590 [Abstract] [Full Text]  
• Leff, A. R., Munoz, N. M. (2007). Future Treatment to Lessen Exacerbations of Chronic Obstructive Pulmonary Disease. Proc Am Thorac Soc 4: 659-666 [Abstract] [Full Text]  
• Zheng, J.-P., Yang, L., Wu, Y. M., Chen, P., Wen, Z. G., Huang, W.-J., Shi, Y., Wang, C.-Z., Huang, S.-G., Sun, T.-y., Wang, G.-F., Xiong, S.-D., Zhong, N.-S. (2007). The Efficacy and Safety of Combination Salmeterol (50 {micro}g)/Fluticasone Propionate (500 {micro}g) Inhalation Twice Daily Via Accuhaler in Chinese Patients With COPD. Chest 132: 1756-1763 [Abstract] [Full Text]  
• Calverley, P M A, Wedzicha, J A (2007). Chronic obstructive pulmonary disease past, present and future. Thorax 62: 1026-1027 [Full Text]  
• Qaseem, A., Snow, V., Shekelle, P., Sherif, K., Wilt, T. J., Weinberger, S., Owens, D. K., for the Clinical Efficacy Assessment Subcommittee, (2007). Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline from the American College of Physicians. ANN INTERN MED 147: 633-638 [Abstract] [Full Text]  
• Wilt, T. J., Niewoehner, D., MacDonald, R., Kane, R. L. (2007). Management of Stable Chronic Obstructive Pulmonary Disease: A Systematic Review for a Clinical Practice Guideline. ANN INTERN MED 147: 639-653 [Abstract] [Full Text]  
• Jones, Dr. R. (2007). Too little, too late the patients' perspective on education for COPD. Chronic Respiratory Disease 4: 189-190  
• D'Urzo, A. D. (2007). {beta}-Agonists: all the facts please. cfp 53: 1884-1886 [Full Text]  
• Salpeter, S. R. (2007). Response. cfp 53: 1886-1886 [Full Text]  
• Barnes, N. (2007). Reducing inflammation in COPD: the evidence builds. Thorax 62: 927-928 [Full Text]  
• Agusti, A. (2007). Systemic Effects of Chronic Obstructive Pulmonary Disease: What We Know and What We Don't Know (but Should). Proc Am Thorac Soc 4: 522-525 [Abstract] [Full Text]  
• Hanania, N. A., Donohue, J. F. (2007). Pharmacologic Interventions in Chronic Obstructive Pulmonary Disease: Bronchodilators. Proc Am Thorac Soc 4: 526-534 [Abstract] [Full Text]  
• Suissa, S., McGhan, R., Niewoehner, D., Make, B. (2007). Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease. Proc Am Thorac Soc 4: 535-542 [Abstract] [Full Text]  
• Anzueto, A., Sethi, S., Martinez, F. J. (2007). Exacerbations of Chronic Obstructive Pulmonary Disease. Proc Am Thorac Soc 4: 554-564 [Abstract] [Full Text]  
• Tino, G., Ware, L. B., Moss, M. (2007). Clinical Year in Review IV: Chronic Obstructive Pulmonary Disease, Nonpulmonary Critical Care, Diagnostic Imaging, and Mycobacterial Disease. Proc Am Thorac Soc 4: 494-498 [Full Text]  
• Fabbri, L. M., Boschetto, P., Mapp, C. E. (2007). COPD Guidelines: The Important Thing Is Not to Stop Questioning. Am. J. Respir. Crit. Care Med. 176: 527-528 [Full Text]  
• Soriano, J. B., Barnes, N. C. (2007). Eppur si muove, or COPD treatment success and inflammation. Eur Respir J 30: 409-410 [Full Text]  
• Salpeter, S. R. (2007). Rebuttal: Should we avoid {beta}-agonists for moderate and severe chronic obstructive pulmonary disease?: YES. cfp 53: 1429-1430 [Full Text]  
• Salpeter, S. R. (2007). Refutation: Faut-il eviter les {beta}-agonistes dans les cas de bronchopneumopathies chroniques obstructives moderees et graves?: OUI. cfp 53: 1432-1433 [Full Text]  
• Aaron, S. D. (2007). Rebuttal: Should we avoid {beta}-agonists for moderate and severe chronic obstructive pulmonary disease?: NO. cfp 53: 1429-1430 [Full Text]  
• Aaron, S. D. (2007). Refutation: Faut-il eviter les {beta}-agonistes dans les cas de bronchopneumopathies chroniques obstructives moderees et graves?: NON. cfp 53: 1432-1432 [Full Text]  
• Calverley, P. M. (2007). . ERR 16: 89-90 [Full Text]  
• Roche, N. (2007). Where current pharmacological therapies fall short in COPD: symptom control is not enough. ERR 16: 98-104 [Abstract] [Full Text]  
• Brusasco, V., Crimi, E., Pellegrino, R. (2007). Airway Inflammation in COPD: Friend or Foe?. Am. J. Respir. Crit. Care Med. 176: 425-426 [Full Text]  
• McIvor, R. A. (2007). Future options for disease intervention: important advances in phosphodiesterase 4 inhibitors. ERR 16: 105-112 [Abstract] [Full Text]  
• Hogg, J. C., Chu, F. S. F., Tan, W. C., Sin, D. D., Patel, S. A., Pare, P. D., Martinez, F. J., Rogers, R. M., Make, B. J., Criner, G. J., Cherniack, R. M., Sharafkhaneh, A., Luketich, J. D., Coxson, H. O., Elliott, W. M., Sciurba, F. C. (2007). Survival after Lung Volume Reduction in Chronic Obstructive Pulmonary Disease: Insights from Small Airway Pathology. Am. J. Respir. Crit. Care Med. 176: 454-459 [Abstract] [Full Text]  
• Schunemann, H. (2007). Salmeterol and fluticasone propionate did not reduce mortality in chronic obstructive pulmonary disease. Evid. Based Med. 12: 114-114 [Full Text]  
• Aaron, S. D. (2007). Should we avoid {beta}-agonists for moderate and severe chronic obstructive pulmonary disease?: NO. cfp 53: 1290-1292 [Full Text]  
• Aaron, S. D. (2007). Faut-il eviter les -agonistes dans les cas de bronchopneumopathies chroniques obstructives moderees et graves?: NON. cfp 53: 1294-1297 [Full Text]  
• Sabroe, I., Parker, L. C, Calverley, P. M A, Dower, S. K, Whyte, M. K B (2007). Pathological networking: a new approach to understanding COPD. Thorax 62: 733-738 [Abstract] [Full Text]  
• Woodhead, M. (2007). Inhaled Corticosteroids Cause Pneumonia ...or Do They?. Am. J. Respir. Crit. Care Med. 176: 111-112 [Full Text]  
• Ernst, P., Gonzalez, A. V., Brassard, P., Suissa, S. (2007). Inhaled Corticosteroid Use in Chronic Obstructive Pulmonary Disease and the Risk of Hospitalization for Pneumonia. Am. J. Respir. Crit. Care Med. 176: 162-166 [Abstract] [Full Text]  
• Maki, R. G., Wathen, J. K., Patel, S. R., Priebat, D. A., Okuno, S. H., Samuels, B., Fanucchi, M., Harmon, D. C., Schuetze, S. M., Reinke, D., Thall, P. F., Benjamin, R. S., Baker, L. H., Hensley, M. L. (2007). Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002. JCO 25: 2755-2763 [Abstract] [Full Text]  
• Ampikaipakan, S. (2007). Combination treatment may help patients with COPD, but does not improve mortality. Thorax 62: 587-587 [Full Text]  
• Rabe, K. F., Beghe, B., Luppi, F., Fabbri, L. M. (2007). Update in Chronic Obstructive Pulmonary Disease 2006. Am. J. Respir. Crit. Care Med. 175: 1222-1232 [Full Text]  
• Kardos, P., Wencker, M., Glaab, T., Vogelmeier, C. (2007). Avoiding Mistakes in Calculating the Number Needed to Treat in Severe COPD. Am. J. Respir. Crit. Care Med. 175: 1347b-1348 [Full Text]  
• Kardos, P., Wencker, M., Glaab, T., Vogelmeier, C. (2007). Hospitalizations with Severe COPD. Am. J. Respir. Crit. Care Med. 175: 1207a-1208 [Full Text]  
• Barnes, P. J., La Vecchia, C., Fabbri, L. M., Duerden, M., Kupfer, Y., Tessler, S., Keaney, N., Calverley, P., Anderson, J., Celli, B. (2007). Prevention of Death in COPD. NEJM 356: 2211-2214 [Full Text]  
• Criner, G. J. (2007). Optimal Treatment of Chronic Obstructive Pulmonary Disease: The Search for the Magic Combination of Inhaled Bronchodilators and Corticosteroids. ANN INTERN MED 146: 606-608 [Full Text]  
• Rabe, K. F. (2007). Treating COPD -- The TORCH Trial, P Values, and the Dodo. NEJM 356: 851-854 [Full Text]  
• Kiley, J. P., Nabel, E. G. (2007). Treating COPD. NEJM 356: 867-867 [Full Text]  
• (2007). Inhaled Therapy and Mortality in COPD. JWatch General 2007: 1-1 [Full Text]